Urolithin A: The Human Data on ‘Anti-Aging’ (Mitophagy, Inflammation, Muscle — What Actually Changes)

In this Energy Code Deep Dive, Dr. Mike Belkowski and moderator Don Bailey break down a 2024 systematic review, “Targeting Aging With Urolithin A in Humans," that focuses on human supplementation studies, not “eat pomegranate and hope.”    You’ll learn what Urolithin A is (and why your gut bacteria can make results wildly inconsistent), why it’s tied to “geroprotection,” and what the clinical evidence actually supports so far: dose-dependent anti-inflammatory signals, changes in mitochondrial/autophagy gene markers, and some improvements in strength/endurance — with a reality check on what didn’t move (ATP max, broad physical function, microbiome composition, body comp, cardiovascular markers in short windows).   Bottom line: promising, practical, but still early. - Article Discussed in Episode: Targeting aging with urolithin A in humans: A systematic review - Key Quotes From Dr. Mike & Don: “It’s like giving two people the same coffee beans, but one of them doesn’t own a coffee grinder!” "It may be improving the ‘quality control and efficiency settings’ more than raw peak horsepower.“ “So it’s like tuning the car so it runs smoother; not necessarily making the top speed higher.” "It’s not a ‘lose 20 pounds and become a triathlete’ pill.” - Key points Urolithin A is a gut-derived metabolite from ellagic acid foods (pomegranate, walnuts, berries), but many people don’t convert well. So food intake ≠ reliable levels. Supplementation “skips the gut lottery” and produces higher, more consistent plasma levels than food sources. The systematic review included 5 human studies / 250 healthy participants with 10–1000 mg/day for 28 days to 4 months. Biggest consistent theme: dose-dependent anti-inflammatory effects (some markers improve more at 1000 mg/day over 4 months). Mitochondria story is nuanced: it may improve gene expression signatures related to mitochondrial activity, autophagy, and fatty-acid oxidation—more “quality control” than peak power. What it didn’t reliably do: increase maximal ATP production, consistently boost biogenesis/dynamics markers, change gut microbiota composition, or meaningfully affect body metrics/cardiovascular outcomes in short trials. Muscle outcomes: some gains in specific strength/endurance measures (e.g., torque metrics; certain fatigue tests), but not universal (e.g., handgrip and broad function didn’t consistently improve). Safety in these studies looked clean (no serious adverse events attributed), but the overall conclusion remains: promising—but the human aging evidence is still young and needs longer/larger trials. - Episode timeline  0:27 — Welcome + urolithin A is trending + episode topic 0:45 — Don’s moderator frame: “does it work / worth it?” 1:04 — Paper ID (2024 systematic review; human supplementation) 1:25 — What urolithin A is + “gut lottery” 2:02 — Why supplement (higher/consistent levels vs food) 2:24 — Why it matters: mitophagy / healthier aging angle 3:05 — What’s included (5 studies, 250 people; 10–1000 mg; 28d–4mo) 3:34 — What improved (inflammation signals, gene markers, some strength/endurance) 4:06 — What didn’t (max ATP, microbiome, broad health/body metrics) 7:02 — Dosing/PK basics (peak ~6h; half-life ~17–22h; plateau ~7d) 7:40 — Safety summary 8:06 — Practical take + “promising but early” conclusion - Dr. Mike's #1 recommendations:   Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com   -   Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook